🇺🇸 FDA

Intelligence Platform

Patents

Browse 134 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12358979

Antibodies that bind interleukin 13 and methods of use

Apogee Therapeutics, Inc. · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12359204

Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and

The Board of Regents of the University of Texas System · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12350322

Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunothera

United Biomedical, Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12291571

Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 rece

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280108

Vaccines having an antigen and interleukin-21 as an adjuvant

Inovio Pharmaceuticals, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12275769

Activatable interleukin 12 polypeptides and methods of use thereof

Werewolf Therapeutics, Inc. · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12247206

Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and

The Board of Regents of the University of Texas System · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12201673

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12157762

Tethered interleukin-15 and interleukin-21

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12077593

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036283

Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions an

Nektar Therapeutics · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12018057

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Protagonist Therapeutics, Inc. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11981739

Chimeric antigen receptor specific for interleukin-23 receptor

SANGAMO THERAPEUTICS FRANCE · Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11981716

Activatable interleukin-2 polypeptides and methods of use thereof

Werewolf Therapeutics, Inc. · Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11944666

Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11939361

Compositions of peptide inhibitors of Interleukin-23 receptor

Protagonist Therapeutics, Inc. · Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11926670

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897874

Compounds and methods for modulating Interleukin-2-inducible T-cell kinase

Corvus Pharmaceuticals, Inc. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11884748

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bow

Protagonist Therapeutics, Inc. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866491

Antibody for binding to interleukin 4 receptor

SuZhou Connect Biopharmaceuticals, Inc. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866503

Methods for treating inflammatory conditions of the airway or lungs by administering antag

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844765

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845808

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Protagonist Therapeutics, Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11807853

Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and

The Board of Regents of the University of Texas System · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted